Found: 11
Select item for more details and to access through your institution.
Clinically Observed Estrogen Receptor Alpha Mutations within the Ligand-Binding Domain Confer Distinguishable Phenotypes.
- Published in:
- Oncology, 2018, v. 94, n. 3, p. 176, doi. 10.1159/000485510
- By:
- Publication type:
- Article
Transcriptome Characterization of Matched Primary Breast and Brain Metastatic Tumors to Detect Novel Actionable Targets.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Low Estrogen Receptor (ER)-Positive Breast Cancer and Neoadjuvant Systemic Chemotherapy: Is Response Similar to Typical ER-Positive or ER-Negative Disease?
- Published in:
- 2018
- By:
- Publication type:
- journal article
Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study.
- Published in:
- Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2021.810023
- By:
- Publication type:
- Article
Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models.
- Published in:
- 2017
- By:
- Publication type:
- journal article
The molecular landscape of premenopausal breast cancer.
- Published in:
- Breast Cancer Research, 2015, v. 17, n. 1, p. 1, doi. 10.1186/s13058-015-0618-8
- By:
- Publication type:
- Article
The molecular landscape of premenopausal breast cancer.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Clinical-pathologic characteristics and response to neoadjuvant chemotherapy in triple-negative low Ki-67 proliferation (TNLP) breast cancers.
- Published in:
- NPJ Breast Cancer, 2022, v. 8, n. 1, p. 1, doi. 10.1038/s41523-022-00415-z
- By:
- Publication type:
- Article
Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022.
- Published in:
- Clinical Breast Cancer, 2020, v. 20, n. 2, p. 145, doi. 10.1016/j.clbc.2019.07.011
- By:
- Publication type:
- Article
Correction: NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer.
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice
NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer.
- Published in:
- Breast Cancer Research, 2024, v. 26, n. 1, p. 1, doi. 10.1186/s13058-024-01823-8
- By:
- Publication type:
- Article